Mindmed joins critical path institute's patient-reported outcome consortium

New york, aug. 17, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading biotech company developing psychedelic-inspired therapies, has joined the critical path institute's ("c-path's") patient-reported outcome (pro) consortium to assist in the development of new approaches to advance medical innovation and regulatory science. c-path ( www.c-path.org ) has multiple active consortia and programs that leverage knowledge sharing to spur innovation.
MNMD Ratings Summary
MNMD Quant Ranking